EDISI CASH TERDUDUK!: Pfizer bersetuju untuk menyelesaikan lebih 10,000 tuntutan mahkamah ke atas ubat Zantac, lapor Bloomberg News

antikorok

Pfizer bersetuju untuk menyelesaikan lebih 10,000 tuntutan mahkamah ke atas ubat Zantac, lapor Bloomberg News

Terjemahan dari Reuters

9 Mei 20245:07 PTG GMT+8

Dikemas kini 21 jam yang lalu



Ilustrasi menunjukkan logo Pfizer
Logo Pfizer dilihat dalam ilustrasi yang diambil, 1 Mei 2022. REUTERS/Dado Ruvic/Ilustrasi/Hak Pelesenan Pembelian Foto Fail


8 Mei (Reuters) - Pfizer (PFE.N)
telah bersetuju untuk menyelesaikan lebih daripada 10,000 tuntutan mahkamah mengenai risiko kanser yang dikaitkan dengan ubat pedih ulu hati Zantac yang telah dihentikan, lapor Bloomberg News pada hari Rabu, memetik sumber dari pihak yang sedia maklum dengan perjanjian itu.

Perjanjian itu meliputi kes-kes di mahkamah negeri A.S. tetapi tidak menyelesaikan pendedahan syarikat kepada tuntutan Zantac sepenuhnya, kata laporan itu, sambil menambah butiran kewangan perjanjian itu tidak didedahkan.

Pfizer tidak menjawab permintaan Reuters bagi mendapatkan komen.

Pada tahun 2020, Pentadbiran Makanan dan Ubat-ubatan A.S. telah mengarahkan pengeluar untuk menarik semula Zantac dan versi generiknya dari pasaran selepas bahan penyebab kanser yang dipanggil NDMA ditemui dalam sampel ubat tersebut.

Beribu-ribu saman mula difailkan di mahkamah persekutuan dan negeri terhadap Pfizer, GSK (GSK.L), Sanofi (SASY.PA) dan Boehringer Ingelheim



English

Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports

By Reuters

May 9, 20245:07 PM GMT+8

Updated 21 hours ago



Illustration shows Pfizer logo
Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights


May 8 (Reuters) - Pfizer (PFE.N)
has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal.

The agreements cover cases in U.S. state courts but don't completely resolve the company's exposure to Zantac claims, the report said, adding that financial details of the deals were not immediately available.

Pfizer did not immediately respond to a Reuters request for comment.

In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after a cancer-causing substance called NDMA was found in samples of the drug.

Thousands of lawsuits began piling up in federal and state courts against Pfizer, GSK (GSK.L), Sanofi (SASY.PA) and Boehringer Ingelheim.


https://www.reuters.com/legal/pf ... rg-news-2024-05-08/

antikorok

Pfizer moves to settle more than 10,000 Zantac cases in state courts: Bloomberg

By Kevin Dunleavy

May 8, 2024 2:38pm



Pfizer
Pfizer had rights to sell heartburn drug Zantac from 1998 to 2006. (Photo by David L. Ryan/The Boston Globe via Getty Images)


Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U.S. state courts, according to Bloomberg, citing anonymous sources.

The terms of the deals weren't available to Bloomberg, the news service said. Last month, when Sanofi settled approximately 4,000 Zantac cases in the U.S., it paid $100 million—or roughly $25,000 per plaintiff—Bloomberg reported at the time.

In an emailed statement, Pfizer did not confirm nor deny the report.

“Pfizer continues to vigorously defend against Zantac lawsuits, which we believe are not supported by reliable science," a spokesperson said. "As we have stated previously, Pfizer has explored and will continue to explore opportunistic settlements of certain cases if appropriate and has settled certain cases,” the company said.

Other companies facing Zantac litigation include GSK and Boehringer Ingelheim. GSK gained approval for Zantac (ranitidine) in 1983 and lost its patent protection for the treatment in 1997.

Pfizer had rights to sell the antacid from 1998 to 2006. In a statement two years ago, Pfizer said it had “substantial indemnification claims against others which have been acknowledged by several manufacturers in their disclosures.” As a result, the company said, “the outcome of the litigation is not likely to be material to Pfizer.”

In 2020, the FDA instructed all companies to take Zantac off the market after it confirmed that the medicine’s main ingredient can transform into a possible carcinogen over time or when exposed to high temperatures. Zantac has since returned to the market with a new formulation that does not include ranitidine.

Over the last year, GSK has hammered out settlements with individual plaintiffs in California, resolving cases before they could go to court. With a longer history with Zantac, GSK faces more claims than the other companies, with Reuters reporting 79,000 outstanding cases in October of last year.

Last week in Chicago, the first trial involving a Zantac user kicked off, with Angela Valadez, 89, claiming she developed colorectal cancer after using the antacid. Her case is against GSK and Boehringer.


RELATED
Sanofi settles 4,000 Zantac state lawsuits, still faces Delaware claims


Companies facing federal litigation, including Pfizer, gained a huge win in 2022 when a Florida district judge rejected the science backing the claims that Zantac can cause cancer. The ruling freed the drugmakers from defending against approximately 50,000 cases that had been consolidated in the Florida federal court.

Throughout the ordeal, the companies have maintained that Zantac can’t cause cancer.

“The company is confident that its Zantac products, which were reviewed and approved by the FDA, did not cause cancer when used as directed,” Pfizer said May 8.


https://www.fiercepharma.com/pha ... tac-cases-bloomberg